Apyx Medical Corporation (APYX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 28 | 49 | 45 | 52 | 48 | 53 | 58 | 59 |
| Operating profit | $m | -6 | -4 | ||||||
| Net profit | $m | -12 | -15 | -23 | -19 | -23 | -11 | -9 | -11 |
| EPS reported | $ | -0.27 | -0.21 | ||||||
| Operating cashflow per share | $ | -0.19 | -0.24 | ||||||
| Capex per share | $ | 0.03 | 0.02 | ||||||
| FCF per share | $ | -0.22 | -0.26 | ||||||
| Free cash flow | $m | -9 | -11 | ||||||
| Net debt | $m | 3 | 8 | ||||||
| Book value equity | $m | 15 | 11 | ||||||
| Book value per share | $ | 0.34 | 0.25 | ||||||
| Number of shares | m | 42.16 | 42.16 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 10.15 | 13.84 | ||||||
| P/S LTM | x | 2.79 | 2.53 | ||||||
| P/FCF LTM | x | -16.19 | -13.36 | ||||||
| EV/EBITDA LTM | x | -33.80 | -94.79 | ||||||
| EV/Sales LTM | x | 2.94 | 2.40 | ||||||
| Earnings Yield LTM | % | -7.60% | -6.71% | ||||||
| FCF Yield | % | -6.18% | -7.49% | ||||||
| Quality | |||||||||
| ROE | % | -77.10% | -78.70% | ||||||
| ROIC | % | -11.60% | -6.78% | ||||||
| Operating margin | % | -12.20% | -6.06% | ||||||
| Gross margin | % | +36.02% | +33.94% | ||||||
| FCF/Sales | % | -17.25% | -18.91% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +9.86% | +21.44% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.23 | -0.28 | ||||||
| Net Debt/EBITDA | x | -1.66 | -7.34 | ||||||
| EBIT/Net interest | x | -1.15 | -0.63 | ||||||
| Net debt/market cap | % | +23.62% | +27.51% | ||||||
| Net debt/Equity | x | 0.21 | 0.72 | ||||||
| Gross debt/equity | x | 2.71 | 3.72 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free